Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132

儲億銀行維持默沙東(MRK.US)買入評級，目標價132美元

moomoo資訊 · 10/09 10:32 · 評級/大行評級

Truist Financial analyst Srikripa Devarakonda maintains $Merck & Co (MRK.US)$ with a buy rating, and sets the target price at $132.

According to TipRanks data, the analyst has a success rate of 54.1% and a total average return of 13.5% over the past year.

AnalystRecentRatingAutoNews_202856_20241008_251ec9d77485961552ca4b126b995df847e727bf_1728484262567228_mm_en

Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:

Expectations are set slightly above consensus for the upcoming Q3 sales, with particular attention on management's commentary regarding Gardasil and, to a lesser extent, Winrevair. While there's a positive outlook on Winrevair, it's anticipated that the resolution of the Gardasil issue in China may take some time, and it's uncertain whether sufficient clarity will be provided to alleviate investor concerns in this quarter.
The firm anticipates a tough quarter for the large-cap biopharmaceutical sector as part of an earnings preview.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

儲億銀行分析師Srikripa Devarakonda維持$默沙東 (MRK.US)$買入評級，目標價132美元。

根據TipRanks數據顯示，該分析師近一年總勝率為54.1%，總平均回報率為13.5%。

AnalystRecentRatingAutoNews_202856_20241008_251ec9d77485961552ca4b126b995df847e727bf_1728484262567228_mm_tc

此外，綜合報道，$默沙東 (MRK.US)$近期主要分析師觀點如下：

對於即將到來的第三季度銷售，預期略高於共識水平，特別關注管理層對加德賽爾和溫瑞娃的評論。雖然對溫瑞娃有積極的展望，但預計中國加德賽爾問題的解決可能需要一些時間，目前尚不確定是否能夠提供足夠的清晰度來緩解投資者在本季度的擔憂。
公司預期大型生物製藥板塊將在季度收益預覽中度過一個艱難的季度。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132

Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132

風險及免責聲明

聲明